Uterine / Endometrial

To find out more about eligibility criteria, click on the ClinicalTrials.gov links and if you are interested in participating, email the coordinator by clicking on the envelope next to the coordinator's name and notify the coordinator. 


Treatment stage
Short name
Protocol Title 
ClinicalTrials.Gov Link
Penn Research Coordinator 
Am I Eligible?
Recurrent MYTHIC Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) NCT04855656 Andrea Standish, RN  Eligibility Criteria
Recurrent MAGNETIC Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) NCT05147272 Andrea Standish, RN  Eligibility Criteria
Recurrent FAETH A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss NCT05300048 Katie Elkins

Eligibility Criteria

Enrollment on Hold

Recurrent ATRIN A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN Eligibility Criteria
Recurrent TPST-1495

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795 Jennifer Louie Eligibility Criteria 
Recurrent Xencor A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer NCT05032040 Isabel Forbes Eligibility Criteria
Recurrent NP-G2-044-P2-01 NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester Eligibility Criteria
Primary Radiation


Whole Pelvis Proton Radiation for Gynecologic Cancer

NCT05758688 Kelly Clark Eligibility Criteria